Cale D Fahrenholtz

5PUBLICATIONS
13CO-AUTHORS
Molecular targetsNeurology and neuromuscular diseasesRadiation therapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 29, 2025
Preclinical Evaluation of Repurposed Antimalarial Artemisinins for the Treatment of Malignant Peripheral Nerve Sheath Tumors.

Heather M Duensing, Jalen M Dixon, Owen R Hunter

|Mar 28, 2024
Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibroma Cells at Doses That Do Not Affect Patient-Matched Schwann Cells.

Bashnona Attiah, Garrett Alewine, Mary-Kate Easter

|Jul 27, 2022
Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors in a Neurofibromin-Dependent Manner.

Garrett Alewine, Jerrica Knight, Adithya Ghantae

|Feb 12, 2021
Combined Photothermal and Ionizing Radiation Sensitization of Triple-Negative Breast Cancer Using Triangular Silver Nanoparticles.

James Sears, Jessica Swanner, Cale D Fahrenholtz

|Jun 28, 2019
Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.

Ning Zhao, Stephanie O Peacock, Chen Hao Lo

Pageof 1

Frequent Collaborators

1 joint publications

Ning Zhao

1 joint publications

Stephanie O Peacock

1 joint publications

Chen Hao Lo

1 joint publications

Laine M Heidman